Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Meta Shares Plunge as AI Spending Spooks Investors

Andreas Sommer by Andreas Sommer
November 2, 2025
in AI & Quantum Computing, Earnings, Nasdaq, Tech & Software
0
Meta Stock
0
SHARES
16
VIEWS
Share on FacebookShare on Twitter

Investors in Meta received a harsh reality check following the company’s third-quarter earnings report. Despite posting robust revenue figures, the social media giant’s stock plummeted by over 11% after CEO Mark Zuckerberg unveiled aggressive spending plans for artificial intelligence development that far exceeded market expectations.

Impressive Revenue Growth Overshadowed

The quarterly performance contained numerous positive indicators that typically would drive investor enthusiasm. Meta’s revenue surged by 26% to reach $51.24 billion, substantially outperforming analyst projections. The company’s advertising business demonstrated particular strength, with delivered ad volume increasing 14% while average ad prices rose 10%. User engagement remained strong across Meta’s family of platforms, with 3.54 billion people accessing services daily.

However, these achievements were dramatically overshadowed by an 83% collapse in earnings per share, which fell to $1.05. This sharp decline resulted from a one-time tax charge approaching $16 billion. Excluding this special item, Meta would have reported earnings of $7.25 per share—a solid performance by most measures.

Aggressive AI Investment Strategy Unveiled

The market’s negative reaction stemmed primarily from Zuckerberg’s forward-looking statements concerning capital expenditure. Meta significantly raised its 2025 investment guidance to between $70 and $72 billion. More concerning to investors, the company indicated “substantially” higher expenditures for 2026, primarily directed toward AI infrastructure and recruiting top technical talent.

Should investors sell immediately? Or is it worth buying Meta?

This strategic shift signals the conclusion of Meta’s recent “efficiency era,” characterized by cost-cutting measures and margin improvement initiatives. Instead, the company is placing an enormous bet on developing what Zuckerberg describes as “superintelligence,” requiring massive investments in data center infrastructure and hiring the world’s leading AI researchers.

Market Skepticism Meets Ambitious Vision

The financial community appears doubtful about Meta’s aggressive AI roadmap. While the core advertising business continues to perform reliably, the Reality Labs division remains a significant financial drain, reporting losses of $4.4 billion in the third quarter alone. The central question facing investors is when these substantial AI investments will begin generating returns.

Looking ahead to the fourth quarter, Meta projects revenue between $56 and $59 billion. The critical factor will be whether Zuckerberg can provide concrete timelines and detailed plans demonstrating how his AI strategy will achieve profitability. Coming quarterly results will reveal whether shareholders remain willing to finance this expensive journey into an AI-dominated future.

Ad

Meta Stock: Buy or Sell?! New Meta Analysis from February 7 delivers the answer:

The latest Meta figures speak for themselves: Urgent action needed for Meta investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Meta: Buy or sell? Read more here...

Tags: META
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Yirendai Stock
AI & Quantum Computing

Yirendai Charts a New Course with Tech-Driven Strategy

February 7, 2026
ServiceNow Stock
AI & Quantum Computing

ServiceNow Shares Face Market Skepticism Despite Record Performance

February 7, 2026
Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026
Next Post
Barrick Mining Stock

Leadership Upheaval at Barrick Gold Sparks Investor Uncertainty

Tennant Stock

Tennant's Critical Earnings Test: Dividend Streak Meets Market Expectations

Metropolitan Bank Stock

Metropolitan Bank's Q3 Performance: A Study in Contrasts

Recommended

C3.ai Stock

Is C3.ai Stock Poised for a Rebound?

2 months ago
MMM stock news

Clarification on Hyperlink and Promotional Fees

2 years ago

XOMA Corporation Expands Portfolio with Acquisition of DSUVIA

2 years ago
Microsoft Stock

A Bold Bet: Peter Thiel’s Hedge Fund Doubles Down on Microsoft

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

ServiceNow Shares Face Market Skepticism Despite Record Performance

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

A New Chapter for First Busey as CrossFirst Merger Finalizes

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Trending

Avanos Medical Stock
Analysis

Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth

by SiterGedge
February 7, 2026
0

Avanos Medical is navigating a critical strategic transformation. The medical device firm is streamlining its operations to...

Guaranty Bancshares Stock

Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion

February 7, 2026
Yirendai Stock

Yirendai Charts a New Course with Tech-Driven Strategy

February 7, 2026
ServiceNow Stock

ServiceNow Shares Face Market Skepticism Despite Record Performance

February 7, 2026
Orthofix Medical Stock

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth
  • Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion
  • Yirendai Charts a New Course with Tech-Driven Strategy

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com